Wenchun Qu on Muck Rack

Wenchun Qu

Rochester
As seen in: Color Research & Application, Mayo Clinic Proceedings
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wenchun

Contact Wenchun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

In Reply: Comment on “Nonsurgical Integrative Treatments for Degenerative Symptomatic Lumbar Spondylolisthesis”

|
By Dan Yan, Brent Bauer, Wenchun Qu
| Mayo Clinic Proceedings Verified
Affiliations & Notes 1Department of Pain Medicine, Mayo Clinic, Jacksonville, FL 2Center for Regenerative Biotherapeutics, Mayo Clinic, Jacksonville, FL 3Department of Pain Medicine, Mayo Clinic, Jacksonville, FL 4Department of Internal Medicine, Mayo Clinic, Rochester, MN 5Robert D. and Patricia E.
Open in Who Shared Issue with article?

The Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds

|
By Wenchun Qu, Zhen J Wang, Christine Hunt
| Mayo Clinic Proceedings Verified
Abstract Objective To evaluate the effectiveness and adverse events of autologous platelet-rich plasma (PRP) in individuals with lower-extremity diabetic ulcers, lower-extremity venous ulcers, and pressure ulcers.
Open in Who Shared Issue with article?

Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome

|
By Zhen Wang, Joshua M. Hare, Guojun Bu, Wenchun Qu
| Color Research & Application Verified
Abstract Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified